Skip to main content
. 2020 Oct 22;12:10469–10477. doi: 10.2147/CMAR.S270258

Table 3.

Univariate and Multivariate Analysis of Risk Factors for OS and PFS in LACC Patients Undergoing NACT

Variables Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
OS
 Response to NACT (no vs yes) 3.250 (1.544–6.838) 0.002 2.453 (1.125–5.348) 0.024
 Age (≥45 y vs <45 y) 1.193 (0.558–2.551) 0.649 - -
 Primary tumor size (≥5 cm vs <5 cm) 1.741 (0.843–3.593) 0.134 - -
 Primary tumor size (≥6 cm vs <6 cm) 1.789 (0.767–4.176) 0.179 - -
 Histology (others vs squamous) 2.048 (0.910–4.609) 0.083 - -
 FIGO stage (IIA1-IIA2 vs IB2) 2.233 (1.022–4.876) 0.044 2.046 (0.933–4.490) 0.074
 Histologic grade (G3 vs G1-G2) 1.357 (0.623–2.957) 0.442 - -
 Lymph node metastasis (positive vs negative) 2.572 (1.253–5.280) 0.010 1.652 (0.711–3.839) 0.243
 LVSI (positive vs negative) 2.560 (1.229–5.334) 0.012 1.686 (0.710–4.006) 0.237
 Parametrial involvement (positive vs negative) 1.979 (0.806–4.860) 0.137 - -
 Surgical margin (positive vs negative) 1.874 (0.255–13.794) 0.538 - -
PFS
 Response to NACT (no vs yes) 2.583 (1.452–4.596) 0.001 2.196 (1.183–4.076) 0.013
 Age (≥45 y vs <45 y) 0.728 (0.408–1.299) 0.283 - -
 Primary tumor size (≥5 cm vs <5cm) 1.700 (0.956–3.025) 0.071 - -
 Primary tumor size (≥6 cm vs <6cm) 2.019 (1.026–3.973) 0.042 2.013 (0.995–4.071) 0.052
 Histology (others vs squamous) 1.276 (0.616–2.641) 0.512 - -
 FIGO stage (IIA1-IIA2 vs IB2) 1.902 (1.040–3.479) 0.037 1.600 (0.868–2.947) 0.132
 Histologic grade (G3 vs G1-G2) 0.874 (0.460–1.660) 0.680 - -
 Lymph node metastasis (positive vs negative) 2.120 (1.180–3.809) 0.012 1.098 (0.531–2.269) 0.801
 LVSI (positive vs negative) 2.344 (1.290–4.261) 0.005 1.392 (0.632–3.063) 0.411
 Parametrial involvement (positive vs negative) 2.703 (1.365–5.353) 0.004 1.688 (0.700–4.068) 0.243
 Surgical margin (positive vs negative) 2.236 (0.541–9.238) 0.266 - -

Abbreviations: HR, hazard ratio; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymph vascular space invasion; OS, overall survival; PFS, progression-free survival.